Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors

In the latest trading session, Pfizer (PFE) closed at $25.22, marking a -2.72% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 1.09% for the day. At the same time, the Dow added 0.14%, and the tech-heavy Nasdaq gained 1.91%. Coming into today, shares of the drugmaker had gained 0.5% in the past month. In that same time, the Medical sector gained 3.16%, while the S&P 500 gained 0.29%. Investors will be eagerly watching for the performance of Pfizer in its upcoming earnings disclosure. The company is forecasted to report an EPS of $0.68, showcasing a 12.82% downward movement from the corresponding quarter of the prior year. In the meantime, our current consensus estimate forecasts the revenue to be $14.4 billion, indicating a 1.71% decline compared to the corresponding quarter of the prior year. For the full year, the Zacks Consensus Estimates project earnings of $2.99 per share and a revenue of $61.64 billion, demonstrating changes of -7.14% and -1.49%, respectively, from the preceding year. Investors should also pay attention to any latest changes in analyst estimates for Pfizer. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. As of now, Pfizer holds a Zacks Rank of #3 (Hold). With respect to valuation, Pfizer is currently being traded at a Forward P/E ratio of 8.68. This valuation marks a discount compared to its industry average Forward P/E of 15.47. The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 97, putting it in the top 40% of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Radical New Technology Could Hand Investors Huge GainsQuantum Computing is the next technological revolution, and it could be even more advanced than AI.While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.See Top Quantum Stocks Now >>This article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks